Relapsed/Refractory Multiple Myeloma Clinical Trial
Official title:
A Phase 1/2 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma
The Phase 1 primary objectives of this study were to assess the safety profile, characterize pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and recommended Phase 2 dose (RPTD) of ABT-199 (venetoclax) when administered in participants with relapsed or refractory multiple myeloma. This study also assessed the safety profile and PK of venetoclax in combination with dexamethasone in participants with t(11;14)-positive multiple myeloma. The Phase 2 primary objective was to further evaluate the objective response rate (ORR) and very good partial response or better rate (VGPR+) in participants with t(11;14)-positive multiple myeloma.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05427812 -
Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04093596 -
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)
|
Phase 1 | |
| Not yet recruiting |
NCT05498545 -
Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT04973605 -
A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05376345 -
BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
| Withdrawn |
NCT05980507 -
An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
| Active, not recruiting |
NCT04601935 -
A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
| Terminated |
NCT06160609 -
Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
|
Phase 1/Phase 2 | |
| Completed |
NCT03309111 -
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT06049290 -
A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05259839 -
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
| Terminated |
NCT03318861 -
Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
| Active, not recruiting |
NCT03590652 -
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
|
Phase 2 | |
| Terminated |
NCT04142619 -
Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)
|
Phase 1 | |
| Completed |
NCT01849848 -
Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT01794507 -
A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
|
Phase 1 | |
| Recruiting |
NCT05160584 -
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
|
||
| Terminated |
NCT03287908 -
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT05862012 -
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT03489525 -
MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
|
Phase 1 |